You can buy or sell ALIM and other stocks, options, ETFs, and crypto commission-free!
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. Read More The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.
52 Week High
52 Week Low
Research And Development
Yahoo FinanceMay 22
Alimera Sciences Announces Launch of Direct-to-Patient Marketing Campaign to Raise Awareness and Educate Consumers on Diabetic Macular Edema and ILUVIEN®
Pilot program to be initiated in four U.S. cities leveraging radio, print and social media channels, with potential for future expansion ILUVIEN’s CONTINUOUS MICRODOSING™ delivery enables patients diagnosed with diabetic macular edema (DME) to maintain vision longer with fewer intra-ocular injections ATLANTA, May 22, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal di...
Yahoo FinanceMay 14
Alimera Sciences to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019
ATLANTA, May 14, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that President and CEO, Rick Eiswirth will present a corporate overview and meet with investors at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019. Mr. Eiswirth’s presentation will be held at 2:00 PM PT in Room 9 of the Beverly Hilton Hotel, 9876 Wilshire Blvd. in Beverly Hills, Calif. Inve...
Expected Jul 29, After Hours